Navigation Links
Bone-Strengthening Drug Guards Against Spread of Breast Cancer
Date:4/1/2010

Zoledronic acid protected against chemotherapy-related bone loss, metastasis, study finds

WEDNESDAY, March 31 (HealthDay News) -- The bone-strengthening drug zoledronic acid (Zometa) reduces the spread of breast cancer by preventing chemotherapy-related bone loss, a new study suggests.

Tumor cells released from the primary breast cancer site often travel to the bone marrow and spread from there to other areas of the body. Chemotherapy speeds up bone turnover, which releases bone-derived growth factors that can promote tumor growth in breast cancer patients.

It's been suggested that zoledronic acid -- which reduces bone loss by slowing the activity of cells that destroy bone -- can make bone marrow a less inviting place for cancer cells.

The new phase 2 trial included 120 women undergoing chemotherapy for locally advanced breast cancer. Some of the patients received 4 milligrams of zoledronic acid every three weeks for one year starting with their first dose of chemotherapy, while others received no zoledronic acid.

Bone marrow samples were taken at the start of the study and again after three months and one year of treatment. At the start of the study, 45.7 percent of patients had detectable tumor cells in their bone marrow. After three months of treatment, women who received zoledronic acid and chemotherapy had fewer detectable tumor cells than those who received chemotherapy alone, according to Rebecca Aft, of the Washington University School of Medicine in St. Louis, and colleagues.

Among women who had no tumor cells in their bone marrow at the start of the study, 87 percent of those in the zoledronic acid group were free of tumor cells at three months, compared with 60 percent of those who received chemotherapy alone. One year after treatment, the rates were 40 percent and 33 percent, respectively, the study authors noted.

The researchers also found that zoledronic acid prevented chemotherapy-related bone loss. Among patients who had low bone mineral density at the start of the study, 44 percent of those who took zoledronic acid had normal bone density after one year and significant decreases in bone-turnover markers at three months and one year.

The study, which appears online March 31 in The Lancet Oncology, was funded by Novartis Pharmaceuticals and Pfizer Inc.

More information

The U.S. National Cancer Institute has more about breast cancer treatments.



-- Robert Preidt



SOURCE: The Lancet Oncology, news release, March 31, 2010


'/>"/>
Copyright©2010 ScoutNews,LLC.
All rights reserved

Related medicine news :

1. OldHouseWeb.com Educates Homeowners on Lead Poisoning Safeguards During National Poison Prevention Week
2. Vitamin D Plus Calcium Guards Against Fractures
3. Exercise Guards White Blood Cells Against Aging
4. Research confirms that some forms of massage help against low-back pain
5. Study finds surgical masks provided effective protection of health-care workers against H1N1
6. IPhone App is New Tool in the Fight Against Breast Cancer
7. Food Safety Attorney Fred Pritzker Calls for Criminal Sanctions Against Food Poisoners
8. Motherhood a Buffer Against Suicide
9. State Legislators Last Line of Defense Against ObamaCare
10. Poorly understood cell plays role in immunity against the flu
11. Study Details Machinery of Immune Protection Against Inflammatory Diseases Like Colitis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/19/2017)... ... February 19, 2017 , ... "At your fingertips" electronic access ... and the Delaware Health Information Network (DHIN) have partnered to improve connectivity of ... health information exchange, DHIN stores and shares real-time health data for more than ...
(Date:2/18/2017)... ... February 17, 2017 , ... ... Sponsored by Axendia, **FDAnews Free Webinar**, March 1, 2017 — 1:30 p.m. ... reduce their regulatory burden? Pay dividends in enhanced and predictable product performance? ...
(Date:2/18/2017)... ... ... Butler Mobility invited Ken Matthews to visit its manufacturing facility and showroom ... impressed with the safety and reliability of the Stannah Stairlift as well as with ... endorsement by Ken Matthews can be heard on News Radio WHP 580 weekdays from ...
(Date:2/18/2017)... ... February 17, 2017 , ... Park Cities Pet Sitter President, Joette White, has ... Life Radio network. The episode, which was posted this week, features a 30-minute ... led to Park Cities Pet Sitter’s being awarded the 2017 National Association of Professional ...
(Date:2/18/2017)... ... February 18, 2017 , ... A new ... and contact points to easily connect elderly veterans of America's armed forces to ... funding. It also conveys material on this year's increase in the Veterans Pension ...
Breaking Medicine News(10 mins):
(Date:2/18/2017)... WASHINGTON, N.Y. , Feb. 17, 2017 /PRNewswire/ ... firm dedicated to protecting the rights of victims ... problems have prompted regulators to call for better ... in 1990. Safety concerns involving power ... Drug Administration (FDA) to investigate how hospitals report ...
(Date:2/17/2017)... LONDON , February 17, 2017 Cryoablation, ... Urology The global ablation technologies market is expected to ... 9.7% from 2022-2027. The market is expected to grow at a ... at $3.3bn in 2016, and $9.05bn in 2026. ... How this report will benefit you ...
(Date:2/17/2017)... , Feb. 17, 2017 Arvinas LLC, ... drugs based on protein degradation, today announced the presentation ... (AR) PROTAC during a poster session at the American ... GU) in Orlando, FL. ... validate our platform and the potential of PROTACs to ...
Breaking Medicine Technology: